Albireo Pharma, Inc.
News
Brandywine Global Investment Management LLC Decreases Stock Position in Albireo Pharma, Inc. (NASDAQ:ALBO)
Zolmax Brandywine Global Investment Management LLC cut its holdings in Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) by 3.7% in the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 42,168 shares of the biopharmaceutical companys stock after selling 1,632 ...\n more…
Point72 Hong Kong Ltd Invests $64,000 in Albireo Pharma, Inc. (NASDAQ:ALBO)
Zolmax Point72 Hong Kong Ltd purchased a new stake in Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) in the 3rd quarter, Holdings Channel.com reports. The institutional investor purchased 3,304 shares of the biopharmaceutical companys stock, valued at approximately $64,000. Several other institutional ...\n more…
Ergoteles LLC Invests $386,000 in Albireo Pharma, Inc. (NASDAQ:ALBO)
Zolmax Ergoteles LLC bought a new position in Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 19,943 shares of the biopharmaceutical companys stock, valued at ...\n more…
78,100 Shares in Albireo Pharma, Inc. (NASDAQ:ALBO) Bought by Point72 Asset Management L.P.
Zolmax Point72 Asset Management L.P. acquired a new position in shares of Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 78,100 shares of the biopharmaceutical companys stock, valued at ...\n more…
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research Aeglea (AGLE) delivered earnings and revenue surprises of 10% and 1.18%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?\n\n Aeglea Biotherapeutics (AGLE) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus ...\n more…
Albireo Pharma, Inc. (NASDAQ:ALBO) Given Average Recommendation of "Hold" by Brokerages
Ticker Report Albireo Pharma, Inc. (NASDAQ:ALBO Get Rating) has earned an average recommendation of Hold from the eight analysts that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy ...\n more…